News
RDX-002, a novel iMTP inhibitor, showed promising results in a Ph2 study, reducing blood fat and weight regain after GLP-1 ...
Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...
GlobalData on MSN17h
Response’s post-GLP-1RA drug reduces weight rebound in Phase II
Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...
Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...
RDX-002 is a first-in-class, potent, and selective inhibitor of intestinal MTP. iMTP is a protein believed to be a key driver of weight gain and metabolic dysregulation in patients treated with ...
RDX-002 is a first-in-class, potent, and selective inhibitor of intestinal MTP. iMTP is a protein believed to be a key driver of weight gain and metabolic dysregulation in patients treated with ...
RDX-002 is a first-in-class, potent, and selective inhibitor of intestinal MTP. iMTP is a protein believed to be a key driver of weight gain and metabolic dysregulation in patients treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback